The competition is fierce! Musk once said that "Tirzepatide", which is more effective than semaglutide, will be launched in China. Who will dominate the weight loss drug market in 2025?

① Today, Eli Lilly and Co announced the official launch of tirzepatide in China, covering both type 2 diabetes and weight loss, and it is already available on some online platforms; ② Musk has claimed that tirzepatide is better than semaglutide, while the market is more focused on the pricing of tirzepatide and whether it will be included in medical insurance; ③ The competition in the GLP-1 sector will become even more intense in 2025, with Jiangsu Hengrui Pharmaceuticals, INNOVENT BIO, and Gan & Lee Pharmaceuticals receiving widespread attention.

cls.cnJan 2 16:20

Express News | Brightgene Bio-Medical Technology Co.,Ltd.: Sulfadiazine sodium injection has received approval from the FDA in the USA.

BreakingsDec 23, 2024 16:45

Express News | The opening of the tenth batch of national Pharmaceutical centralized purchasing has prompted nearly 30 listed companies to announce their products are likely to be selected after the market close.

BreakingsDec 13, 2024 21:24

Express News | Brightgene Bio-Medical Technology Co.,Ltd.: Carboprost injection is intended to be awarded the national pharmaceutical centralized procurement.

BreakingsDec 13, 2024 17:21

BrightGene Bio-Medical Technology Gets Ethics Approval for Phase 3 Trial for Blood Sugar Injection

MT NewswiresDec 5, 2024 17:49

Brightgene bio-medical technology co.,ltd. (688166.SH): Dydrogesterone tablets and its active pharmaceutical ingredient, as well as the active pharmaceutical ingredient of dexmedetomidine tartrate, have been approved for marketing.

brightgene bio-medical technology co.,ltd. (688166.SH) announced that its wholly-owned subsidiary, brightgene pharmaceutical (suzhou) co., ltd...

Zhitong FinanceDec 3, 2024 16:16